The latest report by IMARC Group, titled" Cholera Vaccines Market Report by Vaccine Type (Whole Cell V. Cholerae O1 with Recombinant B-Subunit, Killed Oral O1 and O139), Product (Dukoral, Shanchol, Vaxchora, Euvichol and Euvichol-Plus, and Others), End User (Hospitals and Clinics, Research and Academic Laboratories, and Others), and Region 2025-2033", offers a comprehensive analysis of the industry, which comprises insights on the market. The global cholera vaccines market size reached USD 5.9 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 13.6 Million by 2033, exhibiting a growth rate (CAGR) of 9.6% during 2025-2033.

Factors Affecting the Growth of the Cholera Vaccines Industry:

• Public Health Demand and Outbreaks:

The growth of the cholera vaccines industry is heavily influenced by the frequency and severity of cholera outbreaks. Cholera remains a significant public health concern in many parts of the world, particularly in regions with inadequate sanitation and access to clean water. The recurring nature of outbreaks in countries such as Yemen, Haiti, and several African nations underscores the urgent need for effective vaccination programs. As outbreaks continue to cause high morbidity and mortality, especially in vulnerable populations, there is a growing demand for preventive measures, including vaccines. This demand drives investments in vaccine development and distribution, fostering industry growth. Furthermore, increased awareness and prioritization of cholera prevention by global health organizations, such as the World Health Organization (WHO) and the Global Task Force on Cholera Control (GTFCC), bolster the push for widespread vaccination efforts.

• Advancements in Vaccine Technology:

Technological advancements play a crucial role in the expansion of the cholera vaccines industry. Innovations in biotechnology and vaccine delivery methods have led to the development of more effective and easier-to-administer vaccines. Oral cholera vaccines (OCVs), such as Dukoral, Shanchol, and Euvichol, have improved immunogenicity and can be administered without the need for healthcare professionals, making mass vaccination campaigns more feasible, especially in resource-limited settings. Additionally, ongoing research into new vaccine candidates and formulations aims to enhance the duration of immunity and effectiveness against diverse cholera strains. These technological improvements enhance the overall efficacy of cholera vaccines and reduce production costs and logistical challenges, making vaccines more accessible and affordable for endemic regions.

• International Funding and Support:

The availability of international funding and support is a pivotal factor in the growth of the cholera vaccines industry. Large-scale vaccination programs require substantial financial resources, which are often provided by international donors, governments, and non-governmental organizations (NGOs). Institutions such as Gavi, the Vaccine Alliance, and the Bill & Melinda Gates Foundation have been instrumental in funding cholera vaccination initiatives, ensuring the procurement and distribution of vaccines to high-risk areas. Additionally, coordinated efforts by global health bodies to secure vaccine stockpiles and respond swiftly to outbreaks have underscored the importance of sustained financial commitment. Such support facilitates immediate outbreak response and aids in long-term planning and infrastructure development for routine immunization programs. This financial backing is essential for maintaining and scaling up production capacities, research, and distribution networks, ultimately driving the industry's growth.

For an in-depth analysis, you can request a sample copy of the report: https://www.imarcgroup.com/cholera-vaccines-market/requestsample

Leading Companies Operating in the Global Cholera Vaccines Market

• Astellas Pharma Inc.
• Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.)
• Emergent BioSolutions Inc.
• Eubiologics Co. Ltd.
• Johnson & Johnson
• Merck & Co. Inc.
• Pfizer Inc.
• PharmaChoice Canada Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Valneva SE

Cholera Vaccines Market Report Segmentation:

By Vaccine Type:

• Whole Cell V. Cholerae O1 with Recombinant B-Subunit
• Killed Oral O1 and O139

Whole cell V. cholerae O1 with recombinant B-subunit dominates the market due to its proven efficacy and widespread use in immunization programs.

By Product:

• Dukoral
• Shanchol
• Vaxchora
• Euvichol and Euvichol-Plus
• Others

Dukoral accounts for the largest market share due to its established effectiveness, oral administration convenience, and broad approval for use in multiple countries.

By End User: 

• Hospitals and Clinics
• Research and Academic Laboratories
• Others

Hospitals and clinics represents the largest segment as they are the primary locations for administering vaccines and conducting immunization campaigns.

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

Based on the region, the market has been segmented into North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

Global Cholera Vaccines Market Trends:

The global cholera vaccines market is witnessing significant growth, driven by several key trends. Increasing incidence of cholera outbreaks, particularly in developing regions, has heightened the demand for effective vaccination programs. Besides this, ongoing technological advancements, such as the development of oral cholera vaccines (OCVs) such as Dukoral, Shanchol, and Euvichol, have improved accessibility and administration, facilitating large-scale immunization efforts. Support from international organizations, including WHO and Gavi, has bolstered funding and distribution, ensuring vaccines reach high-risk populations. Additionally, there is a growing emphasis on preventive healthcare and the integration of cholera vaccines into routine immunization schedules. Furthermore, collaborative efforts between governments, NGOs, and private sector players are also driving market expansion. 

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.